Jubilant Pharmova trades higher on the BSE
Jubilant Pharmova is currently trading at Rs. 867.05, up by 1.80 points or 0.21% from its previous closing of Rs. 865.25 on the BSE.
The scrip opened at Rs. 882.65 and has touched a high and low of Rs. 893.30 and Rs. 860.00 respectively. So far 53348 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1309.00 on 07-Nov-2024 and a 52 week low of Rs. 538.80 on 14-Mar-2024.
Last one week high and low of the scrip stood at Rs. 940.00 and Rs. 851.75 respectively. The current market cap of the company is Rs. 13850.29 crore.
The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 23.93% and 25.39% respectively.
Jubilant Pharmova’s subsidiary -- Jubilant Cadista Pharmaceuticals Inc., USA, (Jubilant Cadista) has received Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA) for its solid oral formulations facility at Salisbury, Maryland, USA (Facility) with respect to the inspection conducted by the said regulatory agency in January 2025.
With the receipt of the EIR from the USFDA, the inspection stands successfully closed. Going forward, the said Facility is not expected to manufacture any products as it has closed manufacturing operations.
Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
